Skip to content Skip to footer
Subscribe Now
Viewpoints_Ben Schlatka
VIEWPOINTS

PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors

In an interview with PharmaShots, Ben Schlatka, Vice President, Digital Biomarker Solutions at Medidata share his views on the Agreement with Labcorp to expand decentralized clinical trial capabilities and digital biomarker discovery using Medidata Sensor Cloud Shots: The companies collaborated to advance the use of medical-grade sensors & accelerate biomarker discovery in clinical research including an at-home version of 6MWT…
December 6, 2021

Read more

Viewpoints_Dr. Murat Kalayoglu
VIEWPOINTS

PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease

In an interview with PharmaShots, Dr. Murat Kalayoglu, MD, Ph.D., President, and Chief Executive Officer at Cartesian Therapeutics shared his insights on the P-I/IIa study of Descartes-08 for the treatment of the chronic autoimmune disorder generalized myasthenia gravis (gMG) Shots: Descartes-08 is an autologous T-cell product that is engineered with RNA to encode for CAR The company focuses to use…
December 1, 2021

Read more

Viewpoints_Mark Becker
VIEWPOINTS

PharmaShots Interview: Vivacare’s Mark Becker Shares Insight on the Digital Patient Education Service for Allergic Conditions

In an interview with PharmaShots, Mark Becker, MD, founder, President, and CEO at Vivacare shared his views on the new collaboration with Asthma and Allergy Network to provide a Digital patient education service for allergic conditions Shots: Vivacare and the AAN collaborated to develop a digital patient education service for members regarding allergies, asthma, eczema, and…
November 30, 2021

Read more

Viewpoints_Kathryn Lang
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLC Shots: The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centers In an initial diagnosis, patients treated…
November 29, 2021

Read more

Prescription Drugs Based Top 20 2020
TOP 20

Top 20 Prescription Drugs Based on 2020 Revenue

Innovative horizons are broadening continuously in the field of medicines. Health is not only limited to physical well-being, it also reflects the mental status Pharmaceutical medicines are advancing rapidly in every area of requirement such as immunology, nephrology, oncology, neurology, and Medicines that focuses on treating disease and improving health We have compiled a list of global…
November 25, 2021

Read more

Viewpoints_Wehkamp Shares
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…
November 24, 2021

Read more

Viewpoints_Daniel A. de Boer
VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)

In an interview with PharmaShots, Daniel A. de Boer, Founder, and CEO at ProQR shared his views on the P-II/III Illuminate study of sepofarsen for the treatment of leber congenital amaurosis (LCA10) Shots: The ongoing P-II/III Illuminate study evaluates sepofarsen in 36 adults and children aged ≥8yrs. with LCA10. The results are expected in late Q1 or early Q2’22 In the P-I/II clinical…
November 23, 2021

Read more

Viewpoints_Chris Arendt
VIEWPOINTS

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC Shots: The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor The results showed…
November 22, 2021

Read more

Load more